



27 August 2014

Optiscan Achieves Major Step in Zeiss Product Development

Optiscan is pleased to report that the company has received positive results for all outstanding tests being undertaken to allow clinical use of its sterility solution (disposable sheath) as part of the clinical neurosurgical endomicroscopy system under development for partner Carl Zeiss Meditec, the global leader in neurosurgical visualisation equipment.

The sheath will now be integrated with the previously developed neurosurgical imaging platform allowing integrated use in clinical studies.

Whilst the platform was completed to a clinically usable standard some time ago, the sheath development has been prolonged and has faced many setbacks that have delayed the deployment of the platform into clinical validation, and thus delayed the completion of total system validation. This prolonged process has placed considerable pressure on the company over the past couple of years but it must be stressed that there has been no compromise to our mission of developing the highest quality, functional and enduring products. Now that this final component of our neurosurgical system has completed exhaustive testing, the risk of failures is closed out and the design is fit for its intended use. This now allows the final stages of clinical testing to be completed concurrently with the preparation of regulatory submissions for CE marking and FDA clearance for the product suite.

With the attainment of this major pre-launch milestone, the company is now in a position to address its working capital position which has been placed under significant pressure during the sheath development process, a two year period characterised by a large R&D spend and low income. A suitable working capital position is key to capitalising on this milestone and opening an enduring revenue stream, our top priority.

About Optiscan

Optiscan is a global leader in microscopic imaging technologies for medical markets. Optiscan's unique and patented technologies enable high-powered microscopes to be miniaturised and used inside the body. The technology enables microscopic imaging of up to 1000 times magnification to be achieved. Doctors can use the technology to instantly see cellular level details of tissue without the requirement to surgically remove tissue (biopsy).

Further information:

Gus Holt, Chairman
Tel (613) 9538 3347
GusH@optiscan.com

Bruce Andrew, CFO
Tel (613) 9538 3398
brucea@optiscan.com